SG
CRDL

StoneX Group’s Cardiol Therapeutics CRDL Stock Holding History

StoneX Group’s Portfolio CRDL Stock Details CRDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-10,586
Closed -$5.4K – 489
2022
Q4 		$5.4K Buy
+10,586
New +$6.45K ﹤0.01% 490

Other funds holding CRDL

MI
MMCAP International Grand Cayman, Cayman Islands $1.16B AUM 77.9% 1-Year Est. Return
AI
AXS Investments Port Chester, New York $248M AUM 15.95% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $549M AUM 32.58% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
LNWTC
Laird Norton Wetherby Trust Company Seattle, Washington $4.58B AUM 30.77% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

StoneX Group's CRDL Position: Q1 2023 in Review

StoneX Group sold out of Cardiol Therapeutics (CRDL) in Q1 2023, closing a stake of 10,586 shares — an estimated $5.4K sold.

StoneX Group first reported a position in CRDL in Q4 2022 and held it in 1 quarter. The position peaked at $5.4K in Q4 2022. 35 funds tracked by Wall St. Rank hold CRDL as of Q1 2023.

  • StoneX Group reported no remaining Cardiol Therapeutics position as of Q1 2023 after selling out during the quarter.
  • StoneX Group sold 10,586 Cardiol Therapeutics shares in Q1 2023, an estimated $5.4K.
  • StoneX Group first reported a position in Cardiol Therapeutics in Q4 2022 and held it in 1 quarter.
  • StoneX Group's Cardiol Therapeutics position peaked at $5.4K in Q4 2022.
  • 35 funds tracked by Wall St. Rank held Cardiol Therapeutics as of Q1 2023.

Based on StoneX Group's 13F filing for Q1 2023, filed 11 May 2023.